News articles

News article list

• Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer

  Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer

• Over 500 people a year can access a new life extending lung cancer treatment

  An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.

• Around 400 people with advanced breast cancer are set to benefit from a new treatment

  Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.

• NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance

  Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.

• NICE recommends new drug for people living with obesity

  Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.

• People in England could benefit from new endometrial cancer treatment

  Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.